Although the direct involvement of DPP‐4 in SARS‐CoV‐2 infection needs to be clarified, there is evidence suggesting that DPP‐4 inhibitors might be of potential benefits in patients with COVID‐19. The gene discussed is DPP4; the disease is COVID-19.